West Broward Rheumatology Associates
Welcome,         Profile    Billing    Logout  
 11 Trials 
23 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vrionis, Frank
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
Kimmel, Steven
NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active, not recruiting
3
292
Europe, Japan, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
09/24
12/24
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Recruiting
3
472
Europe, Canada, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
05/25
02/26
NCT04991116: Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Recruiting
3
650
Europe, Canada, Japan, US, RoW
TILD sub-cutaneous (SC) injection
Sun Pharmaceutical Industries Limited
Psoriatic Arthritis
12/28
04/29
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
Grewal, Suneet
FORWARD OL, NCT04762498: A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout

Completed
4
50
US
Pegloticase, Methotrexate (MTX)
Amgen
Uncontrolled Gout, Chronic Gout
05/23
12/23
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Recruiting
4
240
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
NCT04638647 / 2020-004284-98: Secukinumab Open Label Roll-over Extension Protocol

Recruiting
4
715
Europe, US, RoW
Secukinumab s.c. injection
Novartis Pharmaceuticals
Autoimmunity, Inflammation
12/27
02/28
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Active, not recruiting
3
381
Europe, Canada, Japan, US, RoW
Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
09/25
02/26
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
Sherrer, Yvonne
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
Alberts, Alan R
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Active, not recruiting
3
381
Europe, Canada, Japan, US, RoW
Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
09/25
02/26
NEPTUNUS-1, NCT05350072 / 2020-005661-14: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
276
Europe, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), VAY736, Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
Delgado, Vanessa
SARO.20.002, NCT05011305: Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis with Fibrosis

Active, not recruiting
2
180
US, RoW
Saroglitazar Magnesium 2 mg, Investigational Product, Saroglitazar Magnesium 4 mg, Placebo, Comparator Agent
Zydus Therapeutics Inc.
Nonalcoholic Steatohepatitis, Fibrosis
07/25
07/25
NCT03617263: Saroglitazar Magnesium 4 Mg in the Treatment of NAFLD in Women with PCOS (EVIDENCES VII)

Active, not recruiting
2
60
US, RoW
Saroglitazar Magnesium 4 mg Tablet, Not any, Placebo
Zydus Therapeutics Inc.
Non-alcoholic Fatty Liver Disease in Women with PCOS
11/24
11/24
NCT06737042: Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Not yet recruiting
2
285
US
GZR18, Tirzepatide
Gan and Lee Pharmaceuticals, USA
Obesity and Overweight
02/26
06/26
Halpert, Elias
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Recruiting
4
350
Europe, Japan, US, RoW
Belimumab (GSK1550188), BEL (BENLYSTA)
GlaxoSmithKline
Systemic Lupus Erythematosus
04/27
05/29
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Completed
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25

Download Options